Could a simple blood test radically change how liver cancer is detected, especially for those at high risk? This question resonates strongly with recent developments in cancer diagnostics, notably with the FDA's recognition of EvoLiver™, a groundbreaking innovation by Mursla Bio. This designation
Parkinson's disease, a progressive and degenerative brain condition, affects more than 1 percent of individuals over the age of 60 worldwide, leading to symptoms such as slow movements, muscle tremors, stiffness, and difficulty walking. Traditional treatments focus primarily on managing dopamine
Chinese contract research organization GemPharmatech has expanded its presence in the United States with a new facility in San Diego, announced on April 17. The facility is designed for laboratories and housing genetically engineered mouse models, aimed at enhancing their capabilities in offering
With over 300 million people globally suffering from chronic hepatitis B, the disease presents a monumental challenge in the realm of public health. Traditional treatments have mainly focused on suppressing the virus rather than providing a cure, demanding lifelong therapy for many patients.
Allogene Therapeutics, a clinical-stage biotechnology company based in South San Francisco, has achieved a groundbreaking milestone. Their investigational product, ALLO-329, has received three Fast Track Designations (FTDs) from the FDA, marking a significant advancement in the treatment of
Glycomine, a leading biotechnology company based in San Francisco, has achieved a notable milestone by raising $115 million in funding for their pioneering project, GLM101. This development is particularly significant in an economic environment where securing substantial capital remains
